

**From:** [Charles Kandziolka](#)  
**To:** [AGO - High Cost Prescription Drugs](#)  
**Subject:** Nubeqa (darolutamide)  
**Date:** Friday, August 30, 2019 10:14:05 AM

---

Hello,

Pursuant to 18 V.S.A. § 4637, Bayer is notifying the Vermont Attorney General's Office that the introductory wholesale acquisition cost of Nubeqa (darolutamide) is in excess of the Medicare Part D specialty drug threshold.

Product	NDC	WAC
Nubeqa® (darolutamide) 300 mg tablet	50419-395-01	\$11,550.00

Nubeqa is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer.

The marketing and pricing plans are not publicly available. We estimate that approximately 200 patients per month in the US may be prescribed Nubeqa in 2019. Nubeqa was granted Priority Review. On June 2, 2014 Bayer entered into an agreement with Orion to develop Nubeqa for \$68 million upfront and \$45 million for the first US sale. There are additional future royalties based on country approvals and sales.

Kind regards,

Charles Kandziolka  
Strategic Pricing & Reimbursement

---

Bayer: Science For A Better Life

Bayer U.S. Market Access  
100 Bayer Boulevard, PO Box 915  
Building B200, 2B4234  
Whippany, NJ 07981-0915, USA  
Tel: (862) 404-4802  
Mobile: (862) 812-9702  
E-mail: [charles.kandziolka@bayer.com](mailto:charles.kandziolka@bayer.com)